Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Fortunato Morabito, Anna Grazia Recchia, Ernesto Vigna, Cirino Botta, Mamdouh Skafi, Mohammed Abu-Rayyan, Moien Atrash, Sara Galimberti, Lucio Morabito, Hamdi Al-Janazreh, Massimo Martino, Giovanna Cutrona & Massimo Gentile. (2020) An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opinion on Pharmacotherapy 21:1, pages 29-38.
Read now
Read now
Jing Wu, Zhaohua Zhu, Qinghong Yu & Changhai Ding. (2019) Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials. Expert Opinion on Investigational Drugs 28:12, pages 1113-1123.
Read now
Read now
Farzaneh Rahmani, Asghar Aghamohammadi, Hans D. Ochs & Nima Rezaei. (2017) Agammaglobulinemia: comorbidities and long-term therapeutic risks. Expert Opinion on Orphan Drugs 5:7, pages 559-574.
Read now
Read now
Articles from other publishers (38)
卓如 周. (2023) Review of the Efficacy of Bruton Tyrosine Kinase (BTK) Inhibitors on Primary Central Nervous System Lymphoma. Advances in Clinical Medicine 13:01, pages 1083-1091.
Crossref
Crossref
Marcus Maurer, William Berger, Ana Giménez-Arnau, Koremasa Hayama, Vipul Jain, Adam Reich, Sibylle Haemmerle, Karine Lheritier, Pauline Walsh, Summer Xia & Julian Storim. (2022) Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology 150:6, pages 1498-1506.e2.
Crossref
Crossref
Guang Wang, Tong-Xin Yang, Jiong-Ming Li, Zi-Ye Huang, Wen-Bo Yang, Pei Li & Da-Lin He. (2022) Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome. Aging 14:17, pages 7052-7064.
Crossref
Crossref
Vikram J. Singh, Bharti Sharma & Pooja A. Chawla. (2022) Medicinal Attributes of Heterocyclic Compounds in Rheumatoid Arthritis:
Recent Developments and SAR Studies. Current Topics in Medicinal Chemistry 22:22, pages 1821-1846.
Crossref
Crossref
Paweł Kozyra & Monika Pitucha. (2022) Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold—A Short Review of Most Recent Studies 2013–2022. International Journal of Molecular Sciences 23:16, pages 8874.
Crossref
Crossref
Zeyu Yin, Yuanming Zou, Dong Wang, Xinyue Huang, Shengjun Xiong, Liu Cao, Ying Zhang, Yingxian Sun & Naijin Zhang. (2022) Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease. Cell Death Discovery 8:1.
Crossref
Crossref
Jinwan Du. (2021) Synergistic effect of Bruton's tyrosine kinase and TNF‑α in the regulation of rheumatoid arthritis and underlying mechanisms. Experimental and Therapeutic Medicine 23:2.
Crossref
Crossref
Mark Sabat, Douglas R Dougan, Beverly Knight, J. David Lawson, Nicholas Scorah, Christopher R Smith, Ewan R Taylor, Phong Vu, Corey Wyrick, Haixia Wang, Deepika Balakrishna, Mark Hixon, Loui Madakamutil & Donavon McConn. (2021)
Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (
S
)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3
H
-1,2,4-triazol-3-one, by Fragment-Based Drug Design
. Journal of Medicinal Chemistry 64:17, pages 12893-12902.
Crossref
Crossref
Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr & Bruno Cenni. (2021) Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and Translational Science 14:5, pages 1756-1768.
Crossref
Crossref
Datong Zhang, He Gong & Fancui Meng. (2021) Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules 26:16, pages 4907.
Crossref
Crossref
Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo & Andrea Spallarossa. (2021) Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences 22:14, pages 7641.
Crossref
Crossref
Roy Fleischmann. (2021) The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal. The Journal of Rheumatology 48:7, pages 957-959.
Crossref
Crossref
Tobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, Fabian Müller, Armin Schultz, Elliott Klein, Meera Ramanujam, Christian Harcken, Alpana Gupta, Jing Wu, Sabrina Wiebe, Xiujiang Li, Mary Flack, Steven J. Padula, Sudha Visvanathan, Andreas Hünnemeyer & Jianan Hui. (2020) Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. British Journal of Clinical Pharmacology 87:4, pages 1824-1838.
Crossref
Crossref
Jinsha Liu, Joey Paolo Ting, Shams Al-Azzam, Yun Ding & Sepideh Afshar. (2021) Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. International Journal of Molecular Sciences 22:6, pages 2805.
Crossref
Crossref
Yanchun Guo, Han Xue, Shigai Li, Yanyan Wang, Yuexiu Wang, Shuxia Cao & Yufen Zhao. (2020) Electrospray ionization collision induced dissociation of thieno[3,2-d]pyrimidine derivatives. International Journal of Mass Spectrometry 457, pages 116411.
Crossref
Crossref
Jian Liu, Deodial Guiadeen, Arto Krikorian, Xiaolei Gao, James Wang, Sobhana Babu Boga, Abdul-Basit Alhassan, Wensheng Yu, Oleg Selyutin, Younong Yu, Rajan Anand, Jiayi Xu, Joseph Kelly, Joseph L. Duffy, Shilan Liu, Chundao Yang, Hao Wu, Jiaqiang Cai, Chad Bennett, Kevin M. Maloney, Sriram Tyagarajan, Ying-Duo Gao, Thierry O. Fischmann, Jeremy Presland, My Mansueto, Zangwei Xu, Erica Leccese, Jie Zhang-Hoover, Ian Knemeyer, Charles G. Garlisi, Peter Stivers, Philip E. Brandish, Alexandra Hicks, Ronald Kim & Joseph A. Kozlowski. (2020) Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes. Bioorganic & Medicinal Chemistry Letters 30:17, pages 127390.
Crossref
Crossref
Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Rui Zhao, Joshua Galanter, Chin Lee, Julie Rae, Balazs Toth, Nandhini Ramamoorthi, Jason A. Hackney, Alberto Berman, Nemanja Damjanov, Dmytro Fedkov, Slawomir Jeka, Leslie W. Chinn, Michael J. Townsend, Alyssa M. Morimoto, Mark C. Genovese, Alberto Berman, Alejandro Porto, Amelia Granel, Cecilia Asnal, Eduardo Fabian Mysler, Gladys Alicia Testa, Jose Luis Velasco Zamora, Jose Luis Cristian Moreno, Juan Pablo Gulin, Julio Hofman, Maria Rosa Ulla, Mirtha Sabelli, Pablo Alejandro Mannucci, Pablo Jorge Maid, Ana Cláudia Cauceglia Melazzi, Antônio Scafuto Scotton, Antônio Carlos Ximenes, Elisete Funes, Emerson Alves Gimenez, Flora Maria D’Andrea Marcolino, João Francisco Marques Neto, Mauro Waldemar Keiserman, Sebastião Cézar Radominski, Sônia Maria Alvarenga Anti Loduca Lima, Thaís Rohde Pavan, Valderílio Feijó Azevedo, Aneliya Koleva, Antoaneta Toncheva, Daniela Bichovska, Delina Ivanova, Dimitar Penev, Emil Dimitrov, Mariyana Mihaylova, Nadezhda Kapandjieva, Natalia Marinova, Tanya Aleksieva, Tanya Tsvetanova, Tsvetanka Petranova, Valentina Popova, Yuliy Spasov, Carlos Enrique Toro, Carlos Ernesto Arteaga Unigarro, Edwin Jauregui, Javier Dario Marquez Hernandez, Juan Jose Jaller Raad, Patricia Julieta Velez Sanchez, Chang Keun Lee, Chang‐Hee Suh, Eun Young Lee, Sang‐Heon Lee, Seong Wook Kang, Shin‐Seok Lee, Yun Jong Lee, Beatriz Elena Zazueta Montiel, Blanca Irma Pinzon de la O, Daniel Xibille Friedmann, Francisco Rosas Lopez, Isaura Rodriguez Torres, Luis Jara Quezada, Marco Maradiaga Ceceña, Miguel Cortes Hernandez, Miguel Saavedra Salinas, Agnieszka Rapa, Agnieszka Pawtel, Agnieszka Zielinska, Anna Dudek, Anna Rychlewska‐Hanczewska, Anna Strzelecka, Artur Racewicz, Barbara Stasiuk, Katarzyna Gruszecka, Krystyna Dworak, Slawomir Jeka, Tomasz Lowenhoff, Alexey Maslyanskiy, Andrey Rebrov, Diana Krechikova, Elena Zhugrova, Evgeniya Shmidt, Galina Matsievskaya, Irina Vinogradova, Irina Ler, Larisa Eliseeva, Ludmila Savina, Marina Stanislav, Mikhail Sandin, Natalia Zyablova, Nikolay Korshunov, Nino Mosesova, Oksana Polovnikova, Olga Nesmeyanova, Ruzana Samigullina, Sergey Moiseev, Sergey Noskov, Tatiana Raskina, Tatiana Popova, Valeriy Marchenko, Aleksandar Jovanovski, Bojana Stamenkovic, Gorica Ristic, Milijanka Lazarevic, Mirjana Veselinovic, Nada Vujasinovic‐Stupar, Nemanja Damjanov, Predrag Ostojic, Andriy Yagensky, Andriy Gnylorybov, Dmytro Rekalov, Dmytroo Reshotko, Dmytro Fedkov, Georgiy Dzyak, Iurii Gasanov, Ludmila Khimion, Mykola Stanislavchuk, Natalya Prykhodko, Oleg Nadashkevych, Oleg Bortkevych, Orest Abrahamovych, Roman Yatsyshyn, Samvel Turyanytsya, Svitlana Smiyan, Vadym Vizir, Victoria Kachur, Vira Tseluyko, Vladyslav Povoroznyuk, Volodymyr Koshlia, Vyacheslav Zhdan, Yurii Lymar, Yuriy Mostovoy, Angela Hawkes, Arthur Mabaquiao, Cong‐Qiu Chu, Craig Scoville, David Wyatt, Debra Weinstein, Harris McIlwain, Jacqueline Vo, Jeffrey Poiley, Joseph Forstot, Kathryn Dao, Mark Turner, Mark Genovese, Michael Borofsky, Paul Caldron, Philip Waller, Robert Levin, Samy Metyas, Scott Stein, Sharukh Shroff, Shirley Pang, Stanley Cohen, Tauseef Syed & Vishala Chindalore. (2020)
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase
II
Trial
. Arthritis & Rheumatology 72:9, pages 1435-1446.
Crossref
Crossref
Daniela Angst, François Gessier, Philipp Janser, Anna Vulpetti, Rudolf Wälchli, Christian Beerli, Amanda Littlewood-Evans, Janet Dawson, Barbara Nuesslein-Hildesheim, Grazyna Wieczorek, Sascha Gutmann, Clemens Scheufler, Alexandra Hinniger, Alfred Zimmerlin, Enrico G. Funhoff, Robert Pulz & Bruno Cenni. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry 63:10, pages 5102-5118.
Crossref
Crossref
Tamás Németh, Markus Sperandio & Attila Mócsai. (2020) Neutrophils as emerging therapeutic targets. Nature Reviews Drug Discovery 19:4, pages 253-275.
Crossref
Crossref
Xiang Lin & Liwei Lu. 2020. B Cells in Immunity and Tolerance. B Cells in Immunity and Tolerance
145
160
.
Neeraj Kumar, Anita Singh, Dinesh Kumar Sharma & Kamal Kishore. (2019) Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease. Current Signal Transduction Therapy 14:2, pages 107-121.
Crossref
Crossref
Sabrina Solouki, Avery August & Weishan Huang. (2019) Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications. Pharmacology & Therapeutics 201, pages 39-50.
Crossref
Crossref
Xiaofeng Guo, Dongyan Yang, Zhijin Fan, Nailou Zhang, Bin Zhao, Chun Huang, Fangjie Wang, Rongji Ma, Meng Meng & Youcai Deng. (2019) Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines. European Journal of Medicinal Chemistry 178, pages 767-781.
Crossref
Crossref
Xia Yao, Xiuyun Sun, Shuyu Jin, Ling Yang, Hongjiang Xu & Yu Rao. (2019) Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry 62:14, pages 6561-6574.
Crossref
Crossref
Federico Lora Gonzalez, Steven R. Wisniewski, Kishta Katipally, Jason M. Stevens, Victor Rosso, Brendan Mack & Thomas M. Razler. (2019) Systematic Optimization of a Robust Telescoped Process for a BTK Inhibitor with Atropisomer Control by High-Throughput Experimentation, Design of Experiments, and Linear Regression. Organic Process Research & Development 23:6, pages 1143-1151.
Crossref
Crossref
Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G. Batt, Ling Li, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Robin Moore, Zheng Yang, Rodney Vickery, Paul A. Elzinga, Lorell Discenza, Celia D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Yifan Zhang, Elizabeth Heimrich, Kim W. McIntyre, Qian Ruan, Richard A. Westhouse, Ian M. Catlett, Naiyu Zheng, Charu Chaudhry, Jun Dai, Michael A. Galella, Andrew J. Tebben, Matt Pokross, Jianqing Li, Rulin Zhao, Daniel Smith, Richard Rampulla, Alban Allentoff, Michael A. Wallace, Arvind Mathur, Luisa Salter-Cid, John E. Macor, Percy H. Carter, Aberra Fura, James R. Burke & Joseph A. Tino. (2019) Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK). Journal of Medicinal Chemistry 62:7, pages 3228-3250.
Crossref
Crossref
Kai Guo, Xin Bu, Chongfei Yang, Xiaorui Cao, Huan Bian, Qingsheng Zhu, Jinyu Zhu & Dawei Zhang. (2019) Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis. Frontiers in Immunology 9.
Crossref
Crossref
Qingjie Liu, Douglas G. Batt, Charu Chaudhry, Jonathan S. Lippy, Mark A. Pattoli, Neha Surti, Songmei Xu, Percy H. Carter, James R. Burke & Joseph A. Tino. (2018) Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series. Bioorganic & Medicinal Chemistry Letters 28:18, pages 3080-3084.
Crossref
Crossref
Hui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, Ariele Viacava Follis, Anna Gardberg, Andreas Goutopoulos, Roland Grenningloh, Jared Head, Theresa Johnson, Reinaldo Jones, Igor Mochalkin, Federica Morandi, Constantin Neagu & Brian Sherer. (2018) Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Bioorganic & Medicinal Chemistry Letters 28:17, pages 2939-2944.
Crossref
Crossref
Xi Yang & Thomas Papoian. (2018) Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity. Journal of Applied Toxicology 38:9, pages 1166-1176.
Crossref
Crossref
Gregory Beutner, Ronald Carrasquillo, Peng Geng, Yi Hsiao, Eric C. Huang, Jacob Janey, Kishta Katipally, Sergei Kolotuchin, Thomas La Porte, Andrew Lee, Paul Lobben, Federico Lora-Gonzalez, Brendan Mack, Boguslaw Mudryk, Yuping Qiu, Xinhua Qian, Antonio Ramirez, Thomas M. Razler, Thorsten Rosner, Zhongping Shi, Eric Simmons, Jason Stevens, Jianji Wang, Carolyn Wei, Steven R. Wisniewski & Ye Zhu. (2018) Adventures in Atropisomerism: Total Synthesis of a Complex Active Pharmaceutical Ingredient with Two Chirality Axes. Organic Letters 20:13, pages 3736-3740.
Crossref
Crossref
C. Skrabs, W. F. Pickl, T. Perkmann, U. Jäger & A. Gessl. (2018) Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia. Journal of Clinical Pharmacy and Therapeutics 43:1, pages 145-149.
Crossref
Crossref
Maninder Kaur, Pankaj Kumar Singh, Manjinder Singh, Renu Bahadur & Om Silakari. (2017) Molecular dynamics and integrated pharmacophore-based identification of dual
$$\hbox {JAK3/PI3K}\delta $$
JAK3/PI3K
δ
inhibitors. Molecular Diversity 22:1, pages 95-112.
Crossref
Crossref
Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, Maaike van Hoek, Edwin de Zwart, Diana Mittag, Dennis Demont, Saskia Verkaik, Fanny Krantz, Paul G. Pearson, Roger Ulrich & Allard Kaptein. (2017) Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics 363:2, pages 240-252.
Crossref
Crossref
Tommy Tsang Cheung & Iain B. McInnes. (2017) Future therapeutic targets in rheumatoid arthritis?. Seminars in Immunopathology 39:4, pages 487-500.
Crossref
Crossref
Filomena Monica Cavaliere, Alessandro Prezzo, Caterina Bilotta, Metello Iacobini & Isabella Quinti. (2017) The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement. PLOS ONE 12:4, pages e0175961.
Crossref
Crossref
José Antonio Bernal, Mariano Andrés & María Fernanda Palmero. (2017) Bruton's Tyrosine Kinase Inhibitors Could Induce Rheumatoid Arthritis−Like Manifestations: Comment on the Article by Nyhoff et al. Arthritis & Rheumatology 69:2, pages 475-475.
Crossref
Crossref
Qiumeng Zhang, Luyao Zhang, Jie Yu, Heng Li, Shijun He, Wei Tang, Jianping Zuo & Wei Lu. (2017) Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold. RSC Advances 7:42, pages 26060-26069.
Crossref
Crossref